Literature DB >> 7706818

Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.

J G Morris1, G E Losonsky, J A Johnson, C O Tacket, J P Nataro, P Panigrahi, M M Levin.   

Abstract

Vibrio cholerae O139 Bengal has recently emerged as a cause of epidemic cholera in Asia. To evaluate clinical and immunologic responses to infection, V. cholerae O139 Bengal AI1837 was administered to healthy adult North American volunteers. Two of 4 persons ingesting 10(4) cfu became ill (incubation period, 48 h; mean diarrheal stool, 1873 g), as did 7 of 9 persons receiving 10(6) cfu (incubation period, 28 h; mean diarrheal stool, 4548 g). Ill volunteers did not demonstrate a vibriocidal antibody response to the challenge strain or other V. cholerae. Three months later, volunteers were rechallenged with the homologous O139 Bengal strain. Only 1 of 6 persons who had been ill on initial challenge had diarrhea, compared with 11 of 13 controls (P = .01; protective efficacy = 80%). V. cholerae O139 Bengal can cause severe diarrhea typical of cholera, with clinical characteristics and a dose-response similar to those seen with V. cholerae O1 El Tor. A moderately high level of protection against subsequent disease is provided by initial clinical infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706818     DOI: 10.1093/infdis/171.4.903

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Cloning and sequencing of the genes downstream of the wbf gene cluster of Vibrio cholerae serogroup O139 and analysis of the junction genes in other serogroups.

Authors:  S Sozhamannan; Y K Deng; M Li; A Sulakvelidze; J B Kaper; J A Johnson; G B Nair; J G Morris
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

2.  Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139.

Authors:  Stephen R Attridge; Camilla Johansson; Dang D Trach; Firdausi Qadri; Ann-Mari Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

3.  PLASMID MEDIATED DRUG RESISTANCE IN VIBRIO CHOLERAE 0139 BENGAL.

Authors:  R N Misra; N K Debata; A Nagend; T S Hyder; V C Ohri
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 4.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

Review 5.  Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion.

Authors:  C L Sears; J B Kaper
Journal:  Microbiol Rev       Date:  1996-03

6.  Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection.

Authors:  C O Tacket; R K Taylor; G Losonsky; Y Lim; J P Nataro; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

7.  The OmpU outer membrane protein, a potential adherence factor of Vibrio cholerae.

Authors:  V Sperandio; J A Girón; W D Silveira; J B Kaper
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  Emergence and evolution of Vibrio cholerae O139.

Authors:  Shah M Faruque; David A Sack; R Bradley Sack; Rita R Colwell; Yoshifumi Takeda; G Balakrish Nair
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

9.  The Vibrio cholerae genome contains two unique circular chromosomes.

Authors:  M Trucksis; J Michalski; Y K Deng; J B Kaper
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  Association of Vibrio cholerae O1 El Tor and O139 Bengal with the Copepods Acartia tonsa and Eurytemora affinis.

Authors:  Tonya K Rawlings; Gregory M Ruiz; Rita R Colwell
Journal:  Appl Environ Microbiol       Date:  2007-10-19       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.